Aclarion, Inc. (ACON)
NASDAQ: ACON · Real-Time Price · USD
7.00
-0.05 (-0.71%)
Aug 28, 2025, 4:00 PM - Market closed
Aclarion Revenue
Aclarion had revenue of $19.32K in the quarter ending June 30, 2025, with 76.09% growth. This brings the company's revenue in the last twelve months to $62.95K, up 16.68% year-over-year. In the year 2024, Aclarion had annual revenue of $45.72K, down -39.36%.
Revenue (ttm)
$62.95K
Revenue Growth
+16.68%
P/S Ratio
65.22
Revenue / Employee
$10,491
Employees
6
Market Cap
4.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.72K | -29.68K | -39.36% |
| Dec 31, 2023 | 75.40K | 14.96K | 24.75% |
| Dec 31, 2022 | 60.44K | 152.00 | 0.25% |
| Dec 31, 2021 | 60.29K | 11.64K | 23.93% |
| Dec 31, 2020 | 48.65K | 21.76K | 80.88% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ACON News
- 2 months ago - Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum - GlobeNewsWire
- 3 months ago - Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site - GlobeNewsWire
- 3 months ago - Aclarion Announces Texas Back Institute as New CLARITY Trial Site - GlobeNewsWire
- 4 months ago - Aclarion Announces Commercial Agreement with Spine Institute of Louisiana - GlobeNewsWire
- 4 months ago - Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025 - GlobeNewsWire
- 4 months ago - Aclarion Announces Publication of Seminal Nociscan Cost-Effectiveness Analysis - GlobeNewsWire
- 5 months ago - Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub - GlobeNewsWire
- 5 months ago - Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California - GlobeNewsWire